Skip to main content
. Author manuscript; available in PMC: 2009 Aug 5.
Published in final edited form as: Vaccine. 2008 Jun 13;26(33):4150–4159. doi: 10.1016/j.vaccine.2008.05.075

Table 3.

Replication and immunogenicity of parental SLE and chimeric viruses in rhesus monkeys

Virusa Clone No. of monkeys % with viremia Mean no. of days with viremia Mean peak virus titer ± SE (log10PFU/ml)b Geometric mean serum neutralizing antibody titerc Seroconversiond (%)
SLE wt 10 90 3.5 2.1 ± 0.2 39 90
SLE/DEN4 551 6 83 2.2 1.1 ± 0.2 109 100
SLE/DEN4Δ30 545 4 0 0 < 0.7 < 5 0
SLE/DEN4-436,437 41 4 75 2.0 1.0 ± 0.2 28 75
SLE/DEN4-654,655 46 4 0 0 < 0.7 11 0
a

Groups of rhesus monkeys were inoculated SC with 105 PFU of indicated virus. Serum was collected on day 0-6, 8, and 10 for viremia assay and day 28 for antibody titer determination.

b

Virus titer in serum was determined by plaque assay in Vero cells. Mean peak virus titer of SLE-infected monkeys was significantly different from that of other groups as determined by Tukey-Kramer post hoc test (P<0.05).

c

Plaque reduction (60%) neutralizing antibody titers were determined using SLE/DEN4 as target virus. The reciprocal dilution is reported.

d

Seroconversion defined as a 4-fold or greater increase in serum neutralizing antibody level to SLE/DEN4 on day 28.